Oestrus synchronization in buffaloes (Bubalus bubalis)

A study was conducted on 34 Surti buffalo cows to determine the feasibility of synchronizing oestrus using prostaglandin F_2α and a 12-day progesterone intravaginal device. Eighteen cycling buffalo cows having palpable corpora lutea were treated with a single intramuscular injection of 30 mg of prostaglandin F_2α. Three cows exhibited oestrus approximately 54 h after treatment and two of these were diagnosed pregnant 90 days after natural breeding. Sixteen randomly selected post partum cows were treated for 12 days with a progesterone intravaginal device. Ten mg of oestradiol 17β in 5 ml of ether was also injected at the time of insertion of the device. Thirteen cows retained the device for 12 days and 10 of them returned to oestrus 4–5 days after its removal. Eight animals were diagnosed pregnant 90 days after natural breeding. The results indicate that short term progesterone intravaginal device treatment is more reliable than prostaglandin for synchronizing oestrus in buffaloes.     

Comparison of a controlled internal drug release device containing progesterone with intravaginal medroxyprogesterone sponges for estrus synchronization in ewes

Intravaginal progestagens have been used for many years to synchronize estrus in ewes. This experiment compares two such treatments: 60 mg medroxyprogesterone (MAP) sponges and a controlled internal drug release (CIDR) device containing 366 mg natural progesterone. No pregnant mare serum gonadotropin (PMSG) was used. Treatments were given to groups of 10 to 20 ewes for 14 d at various times during breeding season. Rams were introduced 1 d after treatment removal, and day of mating was recorded. Rams were removed after 3 d. Pregnancy was checked with ultrasound 60 d later. There was no diffeence in rate of marking by rams (88%) or pregnancy rate (57%) between treatments. Ewes receiving CIDR devices showed estrus earlier and with closer synchrony (P < 0.01). The CIDR device is comparable to the MAP sponge for estrus synchrony during the breeding season, and reasonable fertility can be achieved without the use of PMSG.     

Fertility of goats following synchronization of estrus with prostagland in F2alpha

Thirty-four mixed breed cyclic does were randomly divided into two groups of 17 each. One group was synchronized for estrus using two i.m. injections of 8 mg PGF2alpha administered 11 days apart. The other group served as controls and was bred at the time of naturally occurring estrus. Both groups were bred by natural service. Ninety-four percent of the treated does came into estrus within a mean (+/- S.E.) of 53 +/- 3 hours after the second injection of 8 mg PGF2alpha. No differences (P > 0.10) in the first service conception rates based on radiography at mid-gestation were observed between the treated and control groups. It was concluded that the use of 8 mg injections of PGF2alpha 11 days apart had no detrimental effects on fertility of goats.     

Induction of oestrus in Saanen goats at early breeding season by intravaginal progesterone sponges (MAP) or by prostaglandin F(2)alpha injections. Effect on different age groups

Twenty-one maiden and 29 pluriparous milking Ankara Saanen goats received either two i.m. injections of PGF(2)alpha (n=25) or intravaginal MAP sponges (n=25) early in November at the start of the breeding season. About twice as many pluriparous goats as maiden goats exhibited estrus after either treatment (87% vs. 47%). Breeding after this induced estrus caused pregnancies in 62% of the pluriparous goats, but only in 24% of the maiden animals. Maximal concentrations of progesterone were reached 11 days after the start of the MAP treatment. Progesterone declined to basal levels two to four days after sponge withdrawal. A significant slower progesterone increase also resulting in lower maximal concentrations could be observed in maiden goats. Luteolysis was evident in all animals within 24 h after PGF(2)alpha injection. Nine goats (six maiden and three pluriparous) did not exhibit Heat after the second injection and showed only a slow increase of progesterone. It seems that noncyclic animals are less sensitive to MAP treatment than to the first PGF(2)alpha injection. Goats at the beginning of the breeding season may react after a premature interruption of corpus luteum function (after second PGF(2)alpha injection) with delayed or inadequate follicular function.     

Serologic diagnosis of Oestrus ovis (Diptera: Oestridae) in naturally infested sheep

Sera from eighteen control sheep supposed to be free from parasitism by Oestrus ovis Linnaeus, 1761, and from 100 sheep raised in an enzootic area of O.ovis infestations were tested to detect anti-Oestrus antibodies by double immunodiffusion (DD) and indirect haemagglutination (IH) tests with somatic crude antigens from first (L1), second (L2) and third (L3) instar of O.ovis larvae. At necropsy, eighty-eight out of 100 sheep from the O.ovis infested area were found to be parasitized while the eighteen control ovines did not show Oestrus larvae. Examination of the sera from the parasitized sheep by DD showed positive results of 42% for L1, 59% for L2 and 18% for L3. Screening the sera with IH gave sensitivities of 100% for L1, 100% for L2 and 97.7% for L3. Sheep, naturally parasitized by gastrointestinal nematodes, presented no cross immune reactions in DD tests with the three larval stages of O.ovis or with L2 larvae in IH tests.     

The synchronization of oestrus and subsequent fertility in ewes following treatment with a synthetic prostaglandin analogue (ONO 453)

ONO 453, a synthetic analogue of prostaglandin F_2α (PGF_2α) is a potent luteolytic agent in cycling ewes when given as a single intramuscular injection. The drug was effective in doses of 2 mg when administered after day 3 of the oestrous cycle. It is well tolerated by ewes, producing no apparent signs of toxicity at 5 mg and only a mild transient increase in the respiratory rate at 10 mg. To synchronise oestrus two dosing regimens were examined; a single i.m. dose of 2 mg administered without reference to the day of the oestrous cycle, and 2 injections of 2 mg administered 7 days apart. With the first method 86.6 per cent of the ewes were in oestrus within 24–50 hours of treatment, with the second, 82 per cent were in oestrus within 30–54 hours. To test the fertility of the oestrus following ONO 453-induced luteolysis, both groups of ewes were run with fertile rams and 86 per cent and 70.8 per cent of those induced by the single or double injection respectively, conceived and lambed.     

Oestrous synchronization in cattle using progesterone and a PGF analogue

A regime consisting of in jections of 150mg and 100mg of progesterone subcutaneously (s.c.) 3 days apart, followed 2 days later by a single injection intramuscularly (i.m.) of a PGF analogue (ICI 80996), and after further 12 hr interval, 1000 i.u. PMSG s.c. was used to synchronize oestrous periods in 16 cows. Eight cows (50%) conceived after insemination with frozen semen after synchronized oestrus; 14 cows came into oestrus over a 36-hr period.     

A radioimmunoassay for fluorogestone acetate (FGA) and its application to the measurement of plasma FGA and progesterone in ewes treated with FGA-impregnated intravaginal sponges

Simultaneous concentrations of endogenous progesterone and exogenous FGA have been measured in ewes treated with FGA-impregnated intravaginal sponges at several times relative to the expected time of release of LH. First, a direct double antibody radioimmunoassay (RIA) for FGA, with good precision, sensitivity and reproducibility, was developed and validated. An oxime derivative was prepared and then conjugated to human serum albumen at the 3-position to produce the antigen. Antibodies raised in New Zealand White rabbits showed little cross-reactivity with related steroids. FGA was estimated in extracted and unextracted plasma; results were indistinguishable. Second, sponges impregnated with 40 mg FGA were inserted into 20 anoestrous crossbred ewes for 12 days; 500 i.u. pregnant mare serum gonadotrophin (PMSG) was injected at withdrawal. Similar sponges were reintroduced into four ewes at each of the intervals 1, 3, 5, and 7 days later; three ewes served as controls. Plasma concentrations of progesterone and FGA were estimated by RIA daily during treatment and at intervals of 2 h for 12 h and at 18 and 24 h after withdrawal. The plasma profiles of FGA during the two successive periods of insertion were remarkably similar. A concentration of 3.0 ng/ml (s.e.m. +/- 0.22) was attained on day 1, falling to 1.5 ng/ml (+/- 0.15) by day 4. Thereafter, the concentration was maintained at 1.1 ng/ml (+/- 0.08). Plasma progesterone concentrations were at basal levels of less than 0.2 ng/ml during the first (acyclic) period of sponge insertion. During the second (cyclic) period there was a marked difference related to the time of sponge insertion. Insertion on day 1 (before LH release) resulted in complete inhibition of luteal activity; insertion on day 3, 5 or 7 was followed by apparently normal luteal function. There was no evidence of any feedback mechanism of exogenous progestagen on endogenous progesterone and no interaction. It is concluded that a 12-day treatment is needed in cyclic ewes for full synchronization and that sponges impregnated with 40 mg FGA will maintain an effective plasma concentration of greater than 1 ng/ml to the end of this period.     

Effect of timing of estradiol benzoate administration upon synchronization of ovulation in suckling Nelore cows (Bos indicus) treated with a progesterone-releasing intravaginal device

The present study investigated how the timing of the administration of estradiol benzoate (EB) impacted the synchronization of ovulation in fixed-time artificial insemination protocols of cattle. To accomplish this, two experiments were conducted, with EB injection occurring at different times: at withdrawal of the progesterone-releasing (P4) intravaginal device or 24h later. The effectiveness of these times was compared by examining ovarian follicular dynamics (Experiment 1, n=30) and conception rates (Experiment 2, n=504). In Experiment 1, follicular dynamics was performed in 30 Nelore cows (Bos indicus) allocated into two groups. On a random day of the estrous cycle (Day 0), both groups received 2mg of EB i.m. and a P4-releasing intravaginal device, which was removed on Day 8, when 400 IU of eCG and 150 microg of PGF were administered. The control group (G-EB9; n=15) received 1mg of EB on Day 9, while Group EB8 (G-EB8; n=15) received the same dose a day earlier. Ovarian ultrasonographic evaluations were performed every 8h after device removal until ovulation. The timing of EB administration (Day 8 compared with Day 9) did affect the interval between P4 device removal to ovulation (59.4+/-2.0 h compared with 69.3+/-1.7h) and maximum diameter of dominant (1.54+/-0.06 acm compared with 1.71+/-0.05 bcm, P=0.03) and ovulatory (1.46+/-0.05 acm compared with 1.58+/-0.04 bcm, P<0.01) follicles. In Experiment 2, 504 suckling cows received the same treatment described in Experiment 1, but insemination was performed as follows: Group EB8-AI48 h (G-EB8-AI48 h; n=119) and Group EB8-AI54 h (G-EB8-AI54 h; n=134) received 1mg of EB on Day 8 and FTAI was performed, respectively, 48 or 54 h after P4 device removal. Group EB9-AI48h (G-EB9-AI48 h; n=126) and Group EB9-AI54 h (G-EB9-AI54 h; n=125) received the same treatments and underwent the same FTAI protocols as G-EB8-AI48 h and G-EB8-AI54 h, respectively; however, EB was administered on Day 9. Conception rates were greater (P<0.05) in G-EB9-AI54 h [63.2% (79/125) a], G-EB9-AI48 h [58.7% (74/126) a] and G-EB8-AI48 h [58.8% (70/119) a] than in G-EB8-AI54 h [34.3% (46/134) b]. We concluded that when EB administration occurred at device withdrawal (D8), the interval to ovulation shortened and dominant and ovulatory follicle diameters decreased. Furthermore, when EB treatment was performed 24h after device removal, FTAI conducted at either 48 or 54 h resulted in similar conception rates. However, EB treatment on the same day as device withdrawal resulted in a lesser conception rate when FTAI was conducted 54 h after device removal.     

Estrus synchronization and conception rate in dairy cattle treated with progestin-impregnated vaginal sponges.

Twelve Israeli-Friesian heifers and cows were treated for estrus synchronization with intravaginal sponges impregnated with 250 mg. medroxyprogesterone acetate (MAP) for a period of 14 days. All sponges were retained throughout the treatment period and 100% of the animals came into estrus 3–7 days after sponge removal. Conception rate from insemination at the synchronized estrus was 60%. It is concluded that further investigation is justified regarding the value of progestin-impregnated sponges as a practical means of estrus synchronization in cattle.     

Parturition control in sows with a prostaglandin analogue (alfaprostol)

The objective of this study was to determine the dose of alfaprostol (18, 19, 20-trinor-17-cyclohexyl-13, 14 didehydro-PGF(2)alpha-methylester) and the day of administration most effective in inducing sows to farrow during normal working hours (0700 to 1700). One-hundred forty multiparous crossbred sows, taken from a herd whose mean gestation length was 114.3 days, were assigned to one of five treatment groups: 1) control vehicle-propylene glycol, 2) 0.5 mg alfaprostol (AP). 3) 1 mg AP, 4) 2 mg AP and 5) 3 mg AP. Sows received an intramuscular injection of AP between 0800 and 0830 on either day 111, 112 or 113 of gestation. Parameters studied included interval from injection to birth of first pig, farrowing interval, total number of pigs born, number born alive, average birth weight, percent stillborn, interval from weaning to next estrus and number born alive next litter. The mean intervals from injection to the birth of the first pig were 55.2 +/- 7.1; 41.1 +/- 5.1; 29.6 +/- 4.0; 24.3 +/- 1.1; 24.8 +/- 0.9 h for groups 1, 2, 3, 4 and 5, respectively (P<0.05). The percentage of sows that farrowed during normal working hours (23 to 33 h after injection) for groups 1, 2, 3, 4 and 5 were 15, 53, 60, 77 and 70%, respectively. Average birth weights (kg) for treatment groups 1, 2, 3, 4 and 5 were 1.54 +/- 0.05; 1.65 +/- 0.05; 1.59 +/- 0.05; 1.54 +/- 0.05 and 1.42 +/- 0.05, respectively (P<0.05). Mean differences in total number of pigs born and number born alive were also statistically significant (P<0.05) but stillbirth rate was not different (P>0.05) among treatment groups. These results indicate that a single injection of 1, 2 or 3 mg of alfaprostol will successfully induce parturition the following day in a majority of the treated sows.     

Estrus and pregnancy rates following synchronization with chronolone intravaginal sponge or norgestomet ear implant in cycling ewes

Two experiments were conducted to evaluate the efficacy of a 3-mg ear implant of norgestomet, left in situ for 10 days, in conjunction with a single injection of 1.5 mg norgestomet and 0.5 mg estradiol valerate (EV) for controlling fertile estrus in the ewe. This treatment regime was compared with a 20-mg cronolone impregnated, intravaginal sponge left in situ for 14 days (Experiment 1) and a modification of the cronolone-sponge-treatment to include a single injection of 1.5 mg norgestomet and 0.5 mg EV (Experiment 2). The percentage of ewes synchronized was not significantly affected by progestin treatment (Experiment 1-cronolone pessary alone, 96%; norgestomet implant and injection of norgestomet and EV, 92%; Experiment 2-cronolone pessary + injection of norgestomet and EV, 84%; Norgestomet implant + injection of norgestomet and EV, 96%). In Experiment 1, the first service pregnancy rate (pregnant of ewes mated) of 80% for cronolone-treated ewes was significantly higher than the 59% observed in norgestomet-treated ewes (P<.05). In Experiment 2, no significant differences were observed in pregnancy rates between the two treatment groups (Cronolone, 57%; Norgestomet, 65%).     

Comparison of control of oestrus and ovulation in sheep by an ear implant (SC-21009) or by intravaginal sponge (cronolone or map)

Oestrus and ovulation were observed in 234 Galway ewes in the breeding season in a preliminary evaluation of an implant progestagen treatment. A miniature ear implant (3 mg SC-21009) was used in a comparison with two intravaginal sponges (30 mg Cronolone and 60 mg medroxy progesterone acetate (MAP)). Each progestagen treatment was used in conjunction with pregnant mare serum gonadotrophin (PMSG) (0, 375 i.u. and 750 i.u.). The percentage of ewes showing oestrus after treatment was significantly affected by progestagen (Cronolone, 95%; MAP, 71%; SC-21009, 74%; P < 0.01), but not by PMSG dose level (0.1 < P < 0.2). Oestrus onset was similar among treatments, but heats ended significantly earlier in implant sheep. Significantly (P < 0.01) more ewes ovulated following Cronolone treatment (92%) than following MAP (74%) or SC-21009 (71%), and there was also a significant effect of PMSG (0, 73%; 375 i.u., 86%; 750 i.u., 93%; P < 0.01). PMSG dose level had a highly significant effect on the mean ovulation rate (0, 1.23; 375 i.u., 1.52; 750 i.u., 2.12; P < 0.001).     

Activation of mitogen-activated protein (MAP) kinase by a MAP kinase-kinase.

Previously it has been shown that acute 12-O-tetradecanoylphorbol-13-acetate treatment of intact U937 cells results in activation of mitogen-activated protein (MAP) kinase and a MAP kinase activator. MAP kinase activator induces phosphorylation of MAP kinase on tyrosine and threonine residues, thereby activating MAP kinase. Here, experiments with the irreversible kinase inhibitor, 5'-p-fluorosulfonylbenzoyladenosine (FSBA), show that MAP kinase activator is in fact a MAP kinase-kinase. Treatment of MAP kinase activator with FSBA results in complete inactivation. This inactivation is prevented by a 10-fold excess of ATP. Inactivation of MAP kinase by FSBA does not affect the extent of threonine/tyrosine phosphorylation induced by MAP kinase-kinase.